在口服液样本中评估抗药物的稳定性
João Martinho1,2, Ana Y Simão1,2, Tiago Rosado1,2,3
1RISE-Health, Departamento de Ciências Médicas, Faculdade de Ciências da Saúde, Universidade da Beira Interior, Av. Infante D. Henrique, 6200-506 Covilhã, Portugal.
Pharmaceuticals (Basel, Switzerland)
|July 30, 2025
概括
对抗药物的干唾液点 (DSS) 分析为治疗药物监测 (TDM) 提供了一种稳定,非侵入性的方法. 最佳的储存包括在黑暗中用甲酸制冷,以确保临床使用药物的稳定性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 分析化学 分析化学
- 临床诊断 临床诊断 临床诊断
背景情况:
- 影响全球5000万,抗药物 (AED) 是主要治疗方法.
- 由于治疗窗口狭窄,治疗药物监测 (TDM) 对AED至关重要.
- 口服液是TDM的一个有前途的替代基因,提供适合不同人群的非侵入性采集.
研究的目的:
- 在干唾液点 (DSS) 样本中评估四种常见的AED的稳定性 (费诺巴尔比他,芬伊托因,碳胺,碳胺-10,11-环氧化物).
- 确定最佳的储存条件,以长时间保持AED分析物的完整性.
- 评估防腐剂,温度,光线和持续时间对口服液中AED稳定性的影响.
主要方法:
- 采集了含有AED的口腔液体样本,并将其作为DSS存储.
- 使用二极管阵列检测 (HPLC-DAD) 的高性能液态色谱进行量化.
- 实验设计 (DOE) 工具系统地评估影响分析物的稳定性的因素.
主要成果:
- 在黑暗中冷藏下,以低度的 Askorbic 酸作为防腐剂实现了最佳稳定性.
- 与没有防腐剂或之前报告的数据的样本相比,10μg/mL的样本的稳定性延长了14天.
- 一个意想不到的发现是,在没有防腐剂的样本中,在0.5μg/mL时分析物的稳定性更高.
结论:
- 这项研究是首次将DSS采集与HPLC-DAD结合起来,以评估AED在口服液中的稳定性.
- 这些发现支持了基于唾液的TDM对AED的可行性,为非侵入性监测策略提供了有价值的见解.
- 优化的储存条件提高了用于药物的临床TDM的DSS的可靠性.
相关概念视频
01:20Antiepileptic Drugs: Potassium Channel Activators
278
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
278
01:21Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
404
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
404
01:20Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
267
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
267
01:08Antiepileptic Drugs: Sodium Channel Blockers
890
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
890
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
451
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
451